BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 23762292)

  • 1. Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells.
    Mehta R; Katta H; Alimirah F; Patel R; Murillo G; Peng X; Muzzio M; Mehta RG
    PLoS One; 2013; 8(6):e65113. PubMed ID: 23762292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer.
    Suh YA; Kim JH; Sung MA; Boo HJ; Yun HJ; Lee SH; Lee HJ; Min HY; Suh YG; Kim KW; Lee HY
    Cancer Lett; 2013 May; 332(1):102-9. PubMed ID: 23348700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.
    Robles AJ; Cai S; Cichewicz RH; Mooberry SL
    Breast Cancer Res Treat; 2016 Jun; 157(3):475-88. PubMed ID: 27255535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
    Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway.
    Murillo G; Peng X; Torres KE; Mehta RG
    Cancer Prev Res (Phila); 2009 Nov; 2(11):942-50. PubMed ID: 19861542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells.
    Mehta RR; Katta H; Kalra A; Patel R; Gupta A; Alimirah F; Murillo G; Peng X; Unni A; Muzzio M; Mehta RG
    Clin Exp Metastasis; 2013 Oct; 30(7):855-66. PubMed ID: 23645347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deguelin, an Akt inhibitor, down-regulates NF-κB signaling and induces apoptosis in colon cancer cells and inhibits tumor growth in mice.
    Kang HW; Kim JM; Cha MY; Jung HC; Song IS; Kim JS
    Dig Dis Sci; 2012 Nov; 57(11):2873-82. PubMed ID: 22623043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer.
    Inoue S; Patil R; Portilla-Arias J; Ding H; Konda B; Espinoza A; Mongayt D; Markman JL; Elramsisy A; Phillips HW; Black KL; Holler E; Ljubimova JY
    PLoS One; 2012; 7(2):e31070. PubMed ID: 22355336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
    Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
    J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
    Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
    Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primaquine Inhibits the Endosomal Trafficking and Nuclear Localization of EGFR and Induces the Apoptosis of Breast Cancer Cells by Nuclear EGFR/Stat3-Mediated c-Myc Downregulation.
    Kim JH; Choi HS; Lee DS
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells.
    Liu T; Yacoub R; Taliaferro-Smith LD; Sun SY; Graham TR; Dolan R; Lobo C; Tighiouart M; Yang L; Adams A; O'Regan RM
    Mol Cancer Ther; 2011 Aug; 10(8):1460-9. PubMed ID: 21690228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
    Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
    Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indole-2-Carboxamide Derivative LG25 Inhibits Triple-Negative Breast Cancer Growth By Suppressing Akt/mTOR/NF-κB Signalling Pathway.
    Xu X; Rajamanickam V; Shu S; Liu Z; Yan T; He J; Liu Z; Guo G; Liang G; Wang Y
    Drug Des Devel Ther; 2019; 13():3539-3550. PubMed ID: 31631978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
    Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
    Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
    Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipyridamole prevents triple-negative breast-cancer progression.
    Spano D; Marshall JC; Marino N; De Martino D; Romano A; Scoppettuolo MN; Bello AM; Di Dato V; Navas L; De Vita G; Medaglia C; Steeg PS; Zollo M
    Clin Exp Metastasis; 2013 Jan; 30(1):47-68. PubMed ID: 22760522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.